Internalization of CD239 highly expressed in breast cancer cells: a potential antigen for antibody-drug conjugates
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Internalization of CD239 highly expressed in breast cancer cells: a potential antigen for antibody-drug conjugates ; volume:8 ; number:1 ; day:26 ; month:4 ; year:2018 ; pages:1-11 ; date:12.2018
Scientific reports ; 8, Heft 1 (26.4.2018), 1-11, 12.2018
- Creator
-
Kikkawa, Yamato
- Contributor
-
Enomoto-Okawa, Yurie
Fujiyama, Aiko
Fukuhara, Takeshi
Harashima, Nozomi
Sugawara, Yumika
Negishi, Yoichi
Katagiri, Fumihiko
Hozumi, Kentaro
Nomizu, Motoyoshi
Ito, Yuji
SpringerLink (Online service)
- DOI
-
10.1038/s41598-018-24961-4
- URN
-
urn:nbn:de:101:1-2018082722501025710155
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:20 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kikkawa, Yamato
- Enomoto-Okawa, Yurie
- Fujiyama, Aiko
- Fukuhara, Takeshi
- Harashima, Nozomi
- Sugawara, Yumika
- Negishi, Yoichi
- Katagiri, Fumihiko
- Hozumi, Kentaro
- Nomizu, Motoyoshi
- Ito, Yuji
- SpringerLink (Online service)
Other Objects (12)
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Antibody–drug conjugates in the treatment of lymphoid neoplasms
Antibody–drug conjugates as an emerging therapy in oncodermatology
Research progress of antibody–drug conjugates in gynecologic cancer
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
From Anthramycin to Pyrrolobenzodiazepine (PBD)‐Containing Antibody–Drug Conjugates (ADCs)
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Antibody–drug conjugates in the treatment of lymphoid neoplasms
Antibody–drug conjugates as an emerging therapy in oncodermatology
Research progress of antibody–drug conjugates in gynecologic cancer
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
From Anthramycin to Pyrrolobenzodiazepine (PBD)‐Containing Antibody–Drug Conjugates (ADCs)
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Antibody–drug conjugates in the treatment of lymphoid neoplasms
Antibody–drug conjugates as an emerging therapy in oncodermatology
Research progress of antibody–drug conjugates in gynecologic cancer
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates